Fig. 4From: Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patientsImpact of ToxNav® testing on average hospital costs per patientBack to article page